Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 6
2006 8
2007 6
2008 7
2009 6
2010 7
2011 2
2012 2
2013 11
2014 8
2015 7
2016 10
2017 12
2018 9
2019 13
2020 18
2021 36
2022 18
2023 11
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR.
Falkenhagen U, Cavallari LH, Duarte JD, Kloft C, Schmidt S, Huisinga W. Falkenhagen U, et al. Among authors: kloft c. Clin Pharmacol Ther. 2024 Apr 24. doi: 10.1002/cpt.3274. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38655898
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Among authors: kloft c. Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38494911
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster KL, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger M. Colombo I, et al. Among authors: kloft c. Eur J Cancer. 2024 Apr;201:113588. doi: 10.1016/j.ejca.2024.113588. Epub 2024 Feb 2. Eur J Cancer. 2024. PMID: 38377773 Free article. Clinical Trial.
Forecasting antimicrobial resistance evolution.
Rolff J, Bonhoeffer S, Kloft C, Leistner R, Regoes R, Hochberg ME. Rolff J, et al. Among authors: kloft c. Trends Microbiol. 2024 Jan 18:S0966-842X(23)00361-X. doi: 10.1016/j.tim.2023.12.009. Online ahead of print. Trends Microbiol. 2024. PMID: 38238231 Review.
183 results